FDA cracks down on J&J sites linked to recalls

WASHINGTON (AP) — Federal officials said Thursday that the consumer health unit of Johnson & Johnson will be barred from resuming operations at a Pennsylvania manufacturing plant linked to millions of bottles of defective medicines until it meets quality standards.

The Food and Drug Administration signed a formal consent decree with the company designed to improve operations at three manufacturing sites linked to multiple recalls of medications last year, including Children's Tylenol, Benadryl and Motrin. The FDA said J&J's McNeil Consumer Healthcare unit violated the law in its production of medications and will be subject to fines of up to $10 million annually if it does …